Physician profile
Mark A Gerard
NPI 1023036670
$10,349.92
in general payments reported to CMS, 2019-2025
49 companies · $2,123 in 2025
The $2,123 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,944 · 2020: $1,493 · 2021: $1,077 · 2022: $1,121 · 2023: $1,432 · 2024: $1,159 · 2025: $2,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,714.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,367.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,215.77 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bausch Health US, LLC | $778.38 | 2020-2025 | Aplenzin |
| Amgen INC. | $663.01 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $575.63 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.03 | 2019-2025 | Jardiance |
| Pfizer INC. | $466.11 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $450.78 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $409.93 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $397.09 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Allergan, INC. | $322.68 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $320.30 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $201.43 | 2019-2021 | |
| Lilly USA, LLC | $194.75 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $180.84 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gerard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.